Laurion Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,547,407
| Closed | -$8.19M | – | 357 |
|
|
2025
Q1 | $8.19M | Sell |
1,547,407
-909,782
| -37% | -$4.81M | 0.21% | 26 |
|
|
2024
Q4 | $16.6M | Buy |
+2,457,189
| New | +$16.6M | 0.3% | 21 |
|
|
2024
Q3 | – | Sell |
-2,901,134
| Closed | -$21.8M | – | 434 |
|
|
2024
Q2 | $21.8M | Buy |
2,901,134
+1,993,518
| +220% | +$15M | 0.26% | 26 |
|
|
2024
Q1 | $9.05M | Hold |
907,616
| – | – | 0.08% | 99 |
|
|
2023
Q4 | $8.95M | Hold |
907,616
| – | – | 0.08% | 56 |
|
|
2023
Q3 | $6.94M | Sell |
907,616
-2,270,563
| -71% | -$17.4M | 0.04% | 73 |
|
|
2023
Q2 | $23.7M | Sell |
3,178,179
-1,647,556
| -34% | -$12.3M | 0.13% | 25 |
|
|
2023
Q1 | $32.2M | Hold |
4,825,735
| – | – | 0.22% | 19 |
|
|
2022
Q4 | $37.2M | Buy |
4,825,735
+238,461
| +5% | +$1.84M | 0.17% | 19 |
|
|
2022
Q3 | $48.8M | Hold |
4,587,274
| – | – | 0.29% | 23 |
|
|
2022
Q2 | $37.3M | Hold |
4,587,274
| – | – | 0.58% | 14 |
|
|
2022
Q1 | $32.8M | Buy |
4,587,274
+663,561
| +17% | +$4.75M | 0.4% | 24 |
|
|
2021
Q4 | $67.2M | Hold |
3,923,713
| – | – | 0.68% | 19 |
|
|
2021
Q3 | $90.3M | Buy |
3,923,713
+65,096
| +2% | +$1.5M | 0.38% | 18 |
|
|
2021
Q2 | $141M | Buy |
+3,858,617
| New | +$141M | 0.78% | 10 |
|